Medical Oncology

Publications | Phd and Masters theses

Advanced search is available through Serval

Publications can be managed by accessing Serval via MyUnil


1035 publications

En préparation
 
Distinct immune signatures are a potent tool in the clinical management of cytokine-related syndrome during immune checkpoint therapy
Daoudlarian Douglas, Segot Amandine, Latifyan Sofiya, Bartolini Robin, Joo Victor, Mederos Nuria, Bouchaab Hasna, Demicheli Rita, Abdelhamid Karim, Ferahta Nabila et al..
[DOI][serval:BIB_818D0F24F67B]
 
Myeloid cell networks determine reinstatement of original immune environments in recurrent ovarian cancer
Ghisoni Eleonora, Benedetti Fabrizio, Minasyan Aspram, Cunnea Paula, Grimm Alizée J., Fahr Noémie, Desbuisson Mathieu, Capt Charlotte, Rayroux Nicolas, Gulhan Doga C. et al..
[DOI][serval:BIB_247B5826C77A]
 
Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study
Petit Pierre-Florent, Daoudlarian Douglas, Latifyan Sofiya, Bouchaab Hasna, Mederos Nuria, Doms Jacqueline, Abdelhamid Karim, Ferahta Nabila, Mencarelli Lucrezia, Joo Victor et al..
[DOI][serval:BIB_34BED0C92D50]
In press
 
Dedicated centres and multinational platforms to improve patient care and address early-onset cancers.
Ben-Aharon I., Smyth E., Wagner A.D. Nature reviews. Cancer. Peer-reviewed.
[DOI][Pmid][serval:BIB_02A7F989E668]
 
Proceedings of the 1st biannual bridging the gaps in lung cancer conference.
Florez N., Patel S.P., Wakelee H., Bazhenova L., Massarelli E., Salgia R., Stiles B., Peters S., Malhotra J., Gadgeel S.M. et al. The oncologist. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A6408ED80877]
 
Identifying the drivers of overall rating of cancer care: Insights from the second wave of the Swiss Cancer Patient Experiences study.
Jolidon V., Eicher M., Peytremann-Bridevaux I., Aebi S., Anchisi S., Bettini A., Chalandon Y., Dietrich P.Y., Duchosal M.A., Dürr D. et al. Cancer. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0A518D224843]
 
Patient-derived mini-colons enable long-term modeling of tumor-microenvironment complexity.
Lorenzo-Martín L.F., Broguiere N., Langer J., Tillard L., Nikolaev M., Coukos G., Homicsko K., Lutolf M.P. Nature biotechnology. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6FBB2EBCBF0E]
 
Calls to action on lung cancer management and research.
Meyer M.L., Hirsch F.R., Bunn P.A., Ujhazy P., Fredrickson D., Berg C.D., Carbone D.P., Halmos B., Singh H., Borghaei H. et al. The oncologist. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_554AFB6D6C3A]
 
Lung Cancer Research and Treatment: Global Perspectives and Strategic Calls to Action.
Meyer M.L., Peters S., Mok T.S., Lam S., Yang P.C., Aggarwal C., Brahmer J., Dziadziuszko R., Felip E., Ferris A. et al. Annals of oncology. Peer-reviewed.
[DOI][Pmid][serval:BIB_F9174A4758FA]
 
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes from the Phase 3 POSEIDON Trial.
Peters S., Cho B.C., Luft A.V., Alatorre-Alexander J., Geater S.L., Laktionov K., Trukhin D., Kim S.W., Ursol G.M., Hussein M. et al. Journal of thoracic oncology. Peer-reviewed.
[DOI][Pmid][serval:BIB_9D803F1B2F65]
 
Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic Non-Small Cell Lung Cancer and Tumor PD-L1 <1%: a Pooled Analysis.
Peters S., Paz-Ares L.G., Reck M., Carbone D.P., Brahmer J.R., Borghaei H., Lu S., O'Byrne K.J., John T., Ciuleanu T.E. et al. Journal of thoracic oncology. Peer-reviewed.
[DOI][Pmid][serval:BIB_89D370D6F09D]
 
Landscape of subsequent therapies in perioperative immunotherapy trials across multiple cancer types.
Semaan K., Nawfal R., Nally E., Janjigian Y.Y., Robert C., Peters S., Powles T., Choueiri T.K. The Lancet. Oncology. Peer-reviewed.
[DOI][Pmid][serval:BIB_7F720847BE91]
 
Treatment of Metastatic Biliary Cancers With Irinotecan and 5-Fluorouracil Based Chemotherapy After Platinum/Gemcitabine Progression: A Systematic Review and Meta-Analysis.
Voutsadakis I.A., Kokkali S., Digklia A. Clinical colorectal cancer. Peer-reviewed.
[DOI][Pmid][serval:BIB_B150D8B52D32]
 
Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanoma.
Weber J., Haque W., Markovic S.N., Salama AKS, Mehmi I., Sullivan R.J., Najjar Y.G., van Akkooi ACJ, Menzies A.M., Long G.V. et al. The oncologist. Peer-reviewed.
[DOI][Pmid][serval:BIB_A8A26871D41B]
2024
 
ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial.
Soo R.A., Dafni U., Han J.Y., Cho B.C., Nadal E., Yeo C.M., Carcereny E., de Castro J., Sala M.A., Coate L. et al., 2024/11/15. Clinical cancer research, 30 (22) pp. 5180-5191. Peer-reviewed.
[DOI][Pmid][serval:BIB_CD5E14800EE8]
 
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.
Blank C.U., Lucas M.W., Scolyer R.A., van de Wiel B.A., Menzies A.M., Lopez-Yurda M., Hoeijmakers L.L., Saw RPM, Lijnsvelt J.M., Maher N.G. et al., 2024/11/07. The New England journal of medicine, 391 (18) pp. 1696-1708. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2A38E708B018]
 
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Skoulidis F., Araujo H.A., Do M.T., Qian Y., Sun X., Cobo A.G., Le J.T., Montesion M., Palmer R., Jahchan N. et al., 2024/11. Nature, 635 (8038) pp. 462-471. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CF6BDAC4D159]
 
Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach.
Ghisoni E., Morotti M., Sarivalasis A., Grimm A.J., Kandalaft L., Laniti D.D., Coukos G., 2024/11. Nature reviews. Clinical oncology, 21 (11) pp. 801-817. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A4CCCAE3C462]
Multi-Modality Imaging to Detect Ischemic and Valvular Heart Disease in Adult Cancer Patients.
Hugelshofer S., Giacomuzzi-Moore B., Auberson D., Tzimas G., Kamani C.H., Masi A., Monney P., Arangalage D., Poku N.K., 2024/11. Echocardiography, 41 (11) pp. e70030. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_BE03E15A4F2F]
 
Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial.
de Gooyer PGM, Verschoor Y.L., van den Dungen LDW, Balduzzi S., Marsman H.A., Geukes Foppen M.H., Grootscholten C., Dokter S., den Hartog A.G., Verbeek WHM et al., 2024/11. Nature medicine, 30 (11) pp. 3284-3290. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_21089C47EC22]
Recurrent benign fibrous histiocytoma of the bone benefits from denosumab followed by malignant transformation: a case report.
Laureline W., Patrick O., Tu N., Stephane C., Ana D., Daniela F., Chiara S., Igor L., Antonia D., 2024/11. Skeletal radiology, 53 (11) pp. 2537-2543. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_22489F1FC523]
 
Cancer Therapy-Induced Encephalitis.
Desbaillets N.P., Hottinger A.F., 2024/10/23. Cancers, 16 (21). Peer-reviewed.
[DOI][Pmid][serval:BIB_3F26575B1292]
 
Abscopal effect induced by cryoablation in a 55-year-old patient with metastatic dedifferentiated liposarcoma: a case report.
Wetterwald L., Papadopoulos S., Tsoumakidou G., Boughdad S., Ferraro D., Koulouris P., Cherix S., Duran R., Digklia A., 2024/10/20. Annals of translational medicine, 12 (5) p. 94. Peer-reviewed.
[DOI][Pmid][serval:BIB_A8DBBBAB3929]
Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update.
Dowlati A., Hummel H.D., Champiat S., Olmedo M.E., Boyer M., He K., Steeghs N., Izumi H., Johnson M.L., Yoshida T. et al., 2024/10/10. Journal of clinical oncology, 42 (29) pp. 3392-3399. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BCFC9F2CF9BF]
 
Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor-Positive Breast Cancer.
O'Regan R.M., Zhang Y., Fleming G.F., Francis P.A., Kammler R., Viale G., Dell'Orto P., Lang I., Bellet M., Bonnefoi H.R. et al., 2024/10/01. JAMA oncology, 10 (10) pp. 1379-1389. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8120F4D3DD80]
Immune Phenotype-Genotype Associations in Primary Clear Cell Renal Cell Carcinoma and Matched Metastatic Tissue.
Sobottka B., Vetter V., Banaei-Esfahani A., Nowak M., Lorch A., Sirek A., Mertz K.D., Brunelli M., Berthold D., de Leval L. et al., 2024/10. Modern pathology, 37 (10) p. 100558. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AD338AA8E2F7]
Multicenter Study on Tumor Budding in Lung Squamous Cell Carcinoma: Comparison Between Biopsy and Resection With Interobserver Variability Assessment.
Maillard M., Neppl C., Zens P., Anex J., Peters S., Krueger T., Berezowska S., 2024/10. Modern pathology, 37 (10) p. 100571. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B6BDDE9C1217]
 
Tumour mutational burden: clinical utility, challenges and emerging improvements.
Budczies J., Kazdal D., Menzel M., Beck S., Kluck K., Altbürger C., Schwab C., Allgäuer M., Ahadova A., Kloor M. et al., 2024/10. Nature reviews. Clinical oncology, 21 (10) pp. 725-742. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9751CA3C1CED]
Fibrotic response to anti-CSF-1R therapy potentiates glioblastoma recurrence.
Watson S.S., Zomer A., Fournier N., Lourenco J., Quadroni M., Chryplewicz A., Nassiri S., Aubel P., Avanthay S., Croci D. et al., 2024/09/09. Cancer cell, 42 (9) pp. 1507-1527.e11. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_ACA88D313315]
 
Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study.
Petit P.F., Daoudlarian D., Latifyan S., Bouchaab H., Mederos N., Doms J., Abdelhamid K., Ferahta N., Mencarelli L., Joo V. et al., 2024/09/04. Annals of oncology. Peer-reviewed.
[DOI][Pmid][serval:BIB_0BA6393BFB37]
 
Nanoplasmonic Single-Tumoroid Microarray for Real-Time Secretion Analysis.
Liu Y.C., Ansaryan S., Tan J., Broguiere N., Lorenzo-Martín L.F., Homicsko K., Coukos G., Lütolf M.P., Altug H., 2024/09. Advanced science, 11 (34) pp. e2401539. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_854452266478]
Pathology of Surgically Resected Lung Cancers Following Neoadjuvant Therapy.
Berezowska S., Keyter M., Bouchaab H., Weissferdt A., 2024/09/01. Advances in anatomic pathology, 31 (5) pp. 324-332. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9497567AE341]
 
Reply to the Letter to the Editor regarding 'Overcoming Barriers in Biomarker Testing' J. García-Foncillas et al.
Bayle A., Chaltiel D., Latino N., Rouleau E., Peters S., Galotti M., Bricalli G., Besse B., Giuliani R., Bonastre J., 2024/09. Annals of oncology, 35 (9) pp. 829-830. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_AA629501C5B1]
 
New promises and challenges in the treatment of advanced non-small-cell lung cancer.
Meyer M.L., Fitzgerald B.G., Paz-Ares L., Cappuzzo F., Jänne P.A., Peters S., Hirsch F.R., 2024/08/24. Lancet, 404 (10454) pp. 803-822. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8FD91D24F28E]
Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma.
Verheijden R.J., Burgers F.H., Janssen J.C., Putker A.E., Veenstra SPGR, Hospers GAP, Aarts MJB, Hehenkamp K.W., Doornebosch VLE, Verhaert M. et al., 2024/08. European journal of cancer, 207 p. 114172. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AB4D3ADF8F4A]
 
KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma.
Budczies J., Romanovsky E., Kirchner M., Neumann O., Blasi M., Schnorbach J., Shah R., Bozorgmehr F., Savai R., Stiewe T. et al., 2024/08. British journal of cancer, 131 (3) pp. 524-533. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0BE58CAF6E6A]
 
ROS1 fusions in resected stage I-III adenocarcinoma: Results from the European Thoracic Oncology Platform Lungscape project.
Speel E.M., Dafni U., Thunnissen E., Hendrik Rüschoff J., O'Brien C., Kowalski J., Kerr K.M., Bubendorf L., Sansano I., Joseph L. et al., 2024/08. Lung cancer, 194 p. 107860. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_40811E238763]
Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non-small cell lung cancer, and renal cell carcinoma.
Luke J.J., Long G.V., Robert C., Carlino M.S., Choueiri T.K., Haas N.B., O'Brien M., Paz-Ares L., Peters S., Powles T. et al., 2024/08. European journal of cancer, 207 p. 114146. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_31E8589807FD]
Status epilepticus management in patients with brain tumors. A cohort study.
Tziakouri A., Hottinger A.F., Novy J., Rossetti A.O., 2024/08. Seizure, 120 pp. 1-4. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_93536ECC1573]
 
Testing new anticancer drugs before curative locoregional therapies: MDICT 2024 recommendations
Methodology for the Development of Innovative Cancer Therapies Taskforce, Stathis A., Le Tourneau C., Tan DSW, Melero I., Garralda E., Peters S., Postel-Vinay S., Yap TA, Martins-Branco D. et al., 2024/08. ESMO Open, 9 (8) p. 103649.
[DOI][WoS][Pmid][serval:BIB_8C8AF2A6E0A9]
Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors and CAR-T Cell Therapy: A Comprehensive Imaging-Based Review.
Pozzessere C., Mazini B., Omoumi P., Jreige M., Noirez L., Digklia A., Fasquelle F., Sempoux C., Dromain C., 2024/07/19. Cancers, 16 (14). Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_21C90DDD7652]
 
Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes.
König D., Sandholzer M.T., Uzun S., Zingg A., Ritschard R., Thut H., Glatz K., Kappos E.A., Schaefer D.J., Kettelhack C. et al., 2024/07/02. Cancer immunology research, 12 (7) pp. 814-821. Peer-reviewed.
[DOI][Pmid][serval:BIB_43CB67C6DE73]
 
Antibody-drug conjugates in lung and breast cancer: current evidence and future directions-a position statement from the ETOP IBCSG Partners Foundation.
Peters S., Loi S., André F., Chandarlapaty S., Felip E., Finn S.P., Jänne P.A., Kerr K.M., Munzone E., Passaro A. et al., 2024/07. Annals of oncology, 35 (7) pp. 607-629. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A510AA983B34]
 
Assessment of endpoint definitions in curative-intent trials for mucosal head and neck squamous cell carcinomas: Head and Neck Cancer International Group consensus recommendations.
Lim A.M., McDowell L., Hurt C., Le Tourneau C., Homma A., Shenouda G., Thomson D.J., Moya-Plana A., Henson C., Szturz P. et al., 2024/07. The Lancet. Oncology, 25 (7) pp. e318-e330. Peer-reviewed.
[DOI][Pmid][serval:BIB_5888F58ED735]
 
Assessment of endpoint definitions in recurrent and metastatic mucosal head and neck squamous cell carcinoma trials: Head and Neck Cancer International Group consensus recommendations.
Lim A.M., Le Tourneau C., Hurt C., Laskar S.G., Steuer C.E., Chow VLY, Szturz P., Henson C., Day A.T., Bates J.E. et al., 2024/07. The Lancet. Oncology, 25 (7) pp. e308-e317. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_AF66A4CF28EE]
 
Brief Report: Impact of Anti-Cancer Treatments on Outcomes of COVID-19 in Patients With Thoracic Cancers: A CCC19 Registry Analysis.
Kulkarni A.A., Hennessy C., Wilson G., Ramesh V., Hwang C., Awosika J., Bakouny Z., Khan H., Vilar-Compte D., McKay R. et al., 2024/07. Clinical lung cancer, 25 (5) pp. e229-e237.e7. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_90D4C066D942]
 
CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma.
Pal S.K., Tran B., Haanen JBAG, Hurwitz M.E., Sacher A., Tannir N.M., Budde L.E., Harrison S.J., Klobuch S., Patel S.S. et al., 2024/07/01. Cancer discovery, 14 (7) pp. 1176-1189. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_380D2196CD9C]
Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial.
Peters S., Gadgeel S.M., Mok T., Nadal E., Kilickap S., Swalduz A., Cadranel J., Sugawara S., Chiu C.H., Yu C.J. et al., 2024/07. Nature medicine, 30 (7) pp. 1923-1932. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4756E179C811]
Gender differences in tumor characteristics, treatment allocation and survival in stage I-III pancreatic cancer: a nationwide study.
Gehrels A.M., Wagner A.D., Besselink M.G., Verhoeven RHA, van Eijck CHJ, van Laarhoven HWM, Wilmink J.W., van der Geest L.G., Dutch Pancreatic Cancer Group, 2024/07. European journal of cancer, 206 p. 114117. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7CEF1784CA34]
 
Population Pharmacokinetics of Trametinib and Impact of Nonadherence on Drug Exposure in Oncology Patients as Part of the Optimizing Oral Targeted Anticancer Therapies Study.
Ravix A., Bandiera C., Cardoso E., Lata-Pedreira A., Chtioui H., Decosterd L.A., Wagner A.D., Schneider M.P., Csajka C., Guidi M., 2024/06/11. Cancers, 16 (12). Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3DC9393D4173]
 
Biological sex and chemotherapy treatment delays in patients with colorectal cancer
Chambers Pinkie, Wagner Anna Dorothea, Almossawi Ofran, Jenkinson Simon, Brooks Gabriel A, Bridgewater John, 2024/06/07. Colorectal Cancer, 13 (1).
[DOI][WoS][serval:BIB_021C55E2D7EB]
 
Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer.
Chalabi M., Verschoor Y.L., Tan P.B., Balduzzi S., Van Lent A.U., Grootscholten C., Dokter S., Büller N.V., Grotenhuis B.A., Kuhlmann K. et al., 2024/06/06. The New England journal of medicine, 390 (21) pp. 1949-1958. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6BBA7AFF15CD]
 
Adoptive Cell Therapy for Solid Tumors: Current Status in Melanoma and Next-Generation Therapies.
Haanen J., Los C., Phan G.Q., Betof Warner A., 2024/06. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 44 (3) pp. e431608. Peer-reviewed.
[DOI][Pmid][serval:BIB_D7A4B8D24794]
 
Beyond Chemoimmunotherapy in Advanced Non-Small Cell Lung Cancer: New Frontiers, New Challenges.
Mountzios G., Naidoo J., Wang C., Creelan B.C., Trotier D.C., Campbell T.C., Peters S., 2024/06. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 44 (3) pp. e432526. Peer-reviewed.
[DOI][Pmid][serval:BIB_67724FD69311]
 
Deep mapping of the cytokine release syndrome inflammatory continuum: Comprehensive grade-specific profiling and differentiation from sepsis in patients receiving immune checkpoint therapy.
Obeid Michel, Daoudlarian Douglas, Segot Amandine, Latifyan Sofiya, Bouchaab Hasna, Mederos Nuria, Abdelhamid Karim, Ferahta Nabila, Stravodimou Athina, Shabafrouz Keyvan et al., 2024/06/01. Journal of Clinical Oncology, 42 (16_suppl) pp. 12129-12129.
[DOI][serval:BIB_928272EB14D0]
 
Effects of CTLA-4 Single Nucleotide Polymorphisms on Toxicity of Ipilimumab-Containing Regimens in Patients With Advanced Stage Melanoma.
de Joode K., Mora A.R., van Schaik RHN, Zippelius A., van der Veldt A., Gerard C.L., Läubli H., Michielin O., von Moos R., Joerger M. et al., 2024/06/01. Journal of immunotherapy, 47 (5) pp. 190-194. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B6930E6F147C]
European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4).
Kroese T.E., Bronzwaer S., van Rossum PSN, Schoppman S.F., Deseyne PRAJ, van Cutsem E., Haustermans K., Nafteux P., Thomas M., Obermannova R. et al., 2024/06. European journal of cancer, 204 p. 114062. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2F4C46C8D49D]
 
High-dimensional longitudinal immune profiling uncovers a dual role of the CXCL9/CXCR3, CXCL13/CXCR5, and CCL11/CCL3 axis in the coupling of immune-related adverse events to immune checkpoint inhibitor response.
Obeid Michel, Joo Victor, Daoudlarian Douglas, Bartolini Robin, Bouchaab Hasna, Latifyan Sofiya, Mederos Nuria, Abdelhamid Karim, Mosimann Valérie, Ferahta Nabila et al., 2024/06/01. Journal of Clinical Oncology, 42 (16_suppl) pp. 2512-2512.
[DOI][serval:BIB_DDD63EA0571E]
NTRK gene fusion testing and management in lung cancer.
Repetto M., Chiara Garassino M., Loong H.H., Lopez-Rios F., Mok T., Peters S., Planchard D., Popat S., Rudzinski E.R., Drilon A. et al., 2024/06. Cancer treatment reviews, 127 p. 102733. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_323D0B921E32]
 
Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R.
Filippi A.R., Bar J., Chouaid C., Christoph D.C., Field J.K., Fietkau R., Garassino M.C., Garrido P., Haakensen V.D., Kao S. et al., 2024/06. ESMO open, 9 (6) p. 103464. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8BA41A1F1CC3]
Spatial Distribution of Recurrence and Long-Term Toxicity Following Dose Escalation to the Dominant Intra-Prostatic Nodule for Intermediate-High-Risk Prostate Cancer: Insights from a Phase I/II Study.
Cloître M., Benkhaled S., Boughdad S., Schaefer N., Prior J.O., Zeverino M., Berthold D., Tawadros T., Meuwly J.Y., Martel P. et al., 2024/05/31. Cancers, 16 (11). Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F69D11E34A2A]
 
Cancer du sein chez l’homme : un combat méconnu [Male breast cancer: a lesser-known battle]
Benchaa H., Stravodimou A., 2024/05/15. Revue medicale suisse, 20 (874) pp. 968-972. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_DD757126534F]
 
L’immunothérapie en oncologie : entre espoirs, défis et équité.
Peters S., Addeo A., Herrera F.G., 2024/05/15. Revue medicale suisse, 20 (874) pp. 951-952. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_7C68C1FA4B60]
 
Prise en charge des métastases osseuses du cancer pulmonaire non à petites cellules [Management of bone metastasis in non-small cell lung cancer]
Apeiranthiti A., Vanniere F., Bayoumy K., Christofis M., Serena A., Mosimann V., Abdelhamid K., Papadopoulos S., Nguyen-Ngoc T., Bouchaab H. et al., 2024/05/15. Revue medicale suisse, 20 (874) pp. 973-977. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_3949B97C5845]
 
Hypnosis-Assisted Awake Craniotomy for Eloquent Brain Tumors: Advantages and Pitfalls.
Cossu G., Vandenbulcke A., Zaccarini S., Gaudet J.G., Hottinger A.F., Rimorini N., Potie A., Beaud V., Guerra-Lopez U., Daniel R.T. et al., 2024/05/05. Cancers, 16 (9). Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_030D0E6436B5]
A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study.
Garon E.B., Cho B.C., Luft A., Alatorre-Alexander J., Geater S.L., Trukhin D., Kim S.W., Ursol G., Hussein M., Lim F.L. et al., 2024/05. Clinical lung cancer, 25 (3) pp. 266-273.e5. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7A92BC1E6EB4]
Essential data variables for a minimum dataset for head and neck cancer trials and clinical research: HNCIG consensus recommendations and database.
Baliga S., Abou-Foul A.K., Parente P., Szturz P., Thariat J., Shreenivas A., Nankivell P., Bertolini F., Biau J., Blakaj D. et al., 2024/05. European journal of cancer, 203 p. 114038. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D13A76D5865C]
PGE2 limits effector expansion of tumour-infiltrating stem-like CD8+ T cells.
Morotti M., Grimm A.J., Hope H.C., Arnaud M., Desbuisson M., Rayroux N., Barras D., Masid M., Murgues B., Chap B.S. et al., 2024/05. Nature, 629 (8011) pp. 426-434. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_5FCB44D6E4AA]
Primary prophylaxis with mTOR inhibitor enhances T cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinoma.
Joo V., Abdelhamid K., Noto A., Latifyan S., Martina F., Daoudlarian D., De Micheli R., Pruijm M., Peters S., Hullin R. et al., 2024/04/30. Nature communications, 15 (1) p. 3664. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4D3A2A46F635]
Long-Term Results of Stereotactic Radiotherapy in Patients with at Least 10 Brain Metastases at Diagnosis.
Kinj R., Hottinger A.F., Böhlen T.T., Ozsahin M., Vallet V., Dunet V., Bouchaab H., Peters S., Tuleasca C., Bourhis J. et al., 2024/04/29. Cancers, 16 (9). Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_51F2E37A9F70]
 
Séquelles émotionnelles et physiques du cancer. Utilité et impact d’un programme de réadaptation [Emotional and physical aftereffects of cancer Utility and impact of a rehabilitation program]
Lagger A., De Micheli R., Hebert D., Hoesli P., 2024/04/24. Revue medicale suisse, 20 (871) pp. 854-857. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_1C288863EE8B]
 
Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors.
Peters S., Angevin E., Alonso-Gordoa T., Rohrberg K., Melero I., Mellado B., Perez-Gracia J.L., Tabernero J., Adessi C., Boetsch C. et al., 2024/04/15. Clinical cancer research, 30 (8) pp. 1630-1641. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CC842A12DADF]
 
Melanoma neoantigen vaccines: Are we getting more personal now?
Latifyan S., Haanen J.B., 2024/04/12. Med, 5 (4) pp. 288-290. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_362339C5E2F1]
 
Adjuvant Alectinib in ALK-Rearranged NSCLC - Here and Now.
Passaro A., Peters S., 2024/04/11. The New England journal of medicine, 390 (14) pp. 1325-1327. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A545924B1B46]
Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol.
Verkerk K., Geurts B.S., Zeverijn L.J., van der Noort V., Verheul HMW, Haanen JBAG, van der Veldt AAM, Eskens FALM, Aarts MJB, van Herpen CML et al., 2024/04. The Lancet regional health. Europe, 39 p. 100875. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_FB1F09F33DB5]
 
Current strategies of cell and gene therapy for solid tumors: results of the joint international ESMO and CTIWP-EBMT survey.
Comoli P., Pentheroudakis G., Ruggeri A., Koehl U., Lordick F., Mooyaart J.E., Hoogenboom J.D., Urbano-Ispizua A., Peters S., Kuball J. et al., 2024/04. Annals of oncology, 35 (4) pp. 404-406. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C8DF2F8D0C82]
Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series.
Vicino A., Hottinger A.F., Latifyan S., Boughdad S., Becce F., Prior J.O., Kuntzer T., Brouland J.P., Dunet V., Obeid M. et al., 2024/04. Journal of neurology, 271 (4) pp. 1947-1958. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_29F8761FAE12]
 
Ischemic Stroke in Cancer: Mechanisms, Biomarkers, and Implications for Treatment.
Costamagna G., Navi B.B., Beyeler M., Hottinger A.F., Alberio L., Michel P., 2024/04. Seminars in thrombosis and hemostasis, 50 (3) pp. 342-359. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CB89FEB62E93]
 
Well-differentiated liposarcomas and dedifferentiated liposarcomas: Systemic treatment options for two sibling neoplasms.
Kyriazoglou A., Pagkali A., Kotsantis I., Economopoulou P., Kyrkasiadou M., Moutafi M., Gavrielatou N., Anastasiou M., Boulouta A., Pantazopoulos A. et al., 2024/04. Cancer treatment reviews, 125 p. 102716. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CB408536C633]
 
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment.
Passaro A., Al Bakir M., Hamilton E.G., Diehn M., André F., Roy-Chowdhuri S., Mountzios G., Wistuba I.I., Swanton C., Peters S., 2024/03/28. Cell, 187 (7) pp. 1617-1635. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_BA8F740FDA43]
Multinational Association of Supportive Care in Cancer (MASCC) expert opinion/guidance on the use of clinically assisted hydration in patients with advanced cancer.
Hayes J., Bruera E., Crawford G., Fleury M., Santos M., Thompson J., Davies A., 2024/03/13. Supportive care in cancer, 32 (4) p. 228. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4B4960C77E68]
Interrogation of endothelial and mural cells in brain metastasis reveals key immune-regulatory mechanisms.
Bejarano L., Kauzlaric A., Lamprou E., Lourenco J., Fournier N., Ballabio M., Colotti R., Maas R., Galland S., Massara M. et al., 2024/03/11. Cancer cell, 42 (3) pp. 378-395.e10. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3AD4E56F8FEC]
 
Efficacy and safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy.
Taylor A.M., McKeown J., Dimitriou F., Jacques S.K., Zimmer L., Allayous C., Yeoh H.L., Haydon A., Ressler J.M., Galea C. et al., 2024/03. European journal of cancer, 199 p. 113561. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CB58FC4C5C60]
Immunohistochemical expression of HMGB1 and related proteins in the skin as a possible tool for determining post-mortem interval: a preclinical study.
De-Giorgio F., Bergamin E., Baldi A., Gatta R., Pascali V.L., 2024/03. Forensic science, medicine, and pathology, 20 (1) pp. 149-165. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D91E32B109C2]
 
Lung Cancer in Switzerland.
Werner R.S., Curioni-Fontecedro A., Mauti L.A., Addeo A., Peters S., Frauenfelder T., Puhan M.A., Haberecker M., Bubendorf L., Finazzi T. et al., 2024/03. Journal of thoracic oncology, 19 (3) pp. 385-394. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_58F75E8C0494]
 
Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy.
Jacques S.K., McKeown J., Grover P., Johnson D.B., Zaremba A., Dimitriou F., Weiser R., Farid M., Namikawa K., Sullivan R.J. et al., 2024/03. European journal of cancer, 199 p. 113563. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_AD78846E78A2]
 
Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma.
Klobuch S., Seijkens TTP, Schumacher T.N., Haanen JBAG, 2024/03. Nature reviews. Clinical oncology, 21 (3) pp. 173-184. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DD86B14A7D89]
2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting.
Herrstedt J., Clark-Snow R., Ruhlmann C.H., Molassiotis A., Olver I., Rapoport B.L., Aapro M., Dennis K., Hesketh P.J., Navari R.M. et al., 2024/02. ESMO open, 9 (2) p. 102195. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_87AB27244127]
Clinical presentation of cardiac symptoms following treatment with tumor-infiltrating lymphocytes: diagnostic challenges and lessons learned.
Borgers JSW, van Schijndel A.W., van Thienen J.V., Klobuch S., Seijkens TTP, Tobin R.P., van Heerebeek L., Driessen-Waaijer A., Rohaan M.W., Haanen JBAG, 2024/02. ESMO open, 9 (2) p. 102383. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_11666E481B80]
 
First-Line Dual Immunotherapy, a Treatment Option in First-Line Metastatic Non-Small-Cell Lung Cancer: Are We Ready to Use It?
Uprety D., Remon J., Peters S., 2024/02/01. Journal of clinical oncology, 42 (4) pp. 378-382. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_FCBB794FB641]
Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastases.
Peters S., Trigo J., Besse B., Moreno V., Navarro A., Eugenia Olmedo M., Paz-Ares L., Grohé C., Antonio Lopez-Vilariño J., Fernández C. et al., 2024/02. Lung cancer, 188 p. 107448. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_251547356E4A]
Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.
Verschoor Y.L., van de Haar J., van den Berg J.G., van Sandick J.W., Kodach L.L., van Dieren J.M., Balduzzi S., Grootscholten C., IJsselsteijn M.E., Veenhof AAFA et al., 2024/02. Nature medicine, 30 (2) pp. 519-530. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CFF0D10D1EFA]
Neratinib as Extended Adjuvant Treatment of HER2-Positive/HR-Positive Early Breast Cancer Patients in Germany, Austria, and Switzerland: Interim Results of the Prospective, Observational ELEANOR Study.
Harbeck N., Wrobel D., Zaiss M., Terhaag J., Guth D., Distelrath A., Zahn M.O., Wuerstlein R., Lorenz A., Bartsch R. et al., 2024/02. Breast care, 19 (1) pp. 1-9. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B7502F26CC0C]
Strategies to decrease inequalities in cancer therapeutics, care and prevention: Proceedings on a conference organized by the Pontifical Academy of Sciences and the European Academy of Cancer Sciences, Vatican City, February 23-24, 2023.
Ringborg U., von Braun J., Celis J., Baumann M., Berns A., Eggermont A., Heard E., Heitor M., Chandy M., Chen C.J. et al., 2024/02. Molecular oncology, 18 (2) pp. 245-279. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E812852CFCF3]
Anatomical Quantitative Volumetric Evaluation of Liver Segments in Hepatocellular Carcinoma Patients Treated with Selective Internal Radiation Therapy: Key Parameters Influencing Untreated Liver Hypertrophy.
Girardet R., Knebel J.F., Dromain C., Vietti Violi N., Tsoumakidou G., Villard N., Denys A., Halkic N., Demartines N., Kobayashi K. et al., 2024/01/30. Cancers, 16 (3). Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_190E90C12E5E]
CIC-DUX4 Chromatin Profiling Reveals New Epigenetic Dependencies and Actionable Therapeutic Targets in CIC-Rearranged Sarcomas.
Bakaric A., Cironi L., Praz V., Sanalkumar R., Broye L.C., Favre-Bulle K., Letovanec I., Digklia A., Renella R., Stamenkovic I. et al., 2024/01/21. Cancers, 16 (2) p. 457. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6DD2EB3D2A00]
 
Oncologie: ce qui a changé en 2023 [Oncology: what's new in 2023]
Jankovic J., Abdelhamid K., Berthold D., Desbaillets N., Bouchaab H., Dei Tos G., Demicheli R., Diciolla A., Digklia A., Ferraro D.A. et al., 2024/01/17. Revue medicale suisse, 20 (856-7) pp. 80-87. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_126B4D3C8255]
A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol.
Mastall M., Roth P., Bink A., Fischer Maranta A., Läubli H., Hottinger A.F., Hundsberger T., Migliorini D., Ochsenbein A., Seystahl K. et al., 2024/01/15. BMC cancer, 24 (1) p. 82. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_5EBA66D24C63]
 
A pharmacist-led interprofessional medication adherence program improved adherence to oral anticancer therapies: The OpTAT randomized controlled trial.
Bandiera C., Cardoso E., Locatelli I., Zaman K., Diciolla A., Digklia A., Stravodimou A., Cristina V., Aedo-Lopez V., Dolcan A. et al., 2024. PloS one, 19 (6) pp. e0304573. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_43D02C36CEB4]
A Review of Ultrasound-Mediated Checkpoint Inhibitor Immunotherapy.
Rivera J., Digklia A., Christou A.S., Anibal J., Vallis K.A., Wood B.J., Stride E., 2024/01. Ultrasound in medicine & biology, 50 (1) pp. 1-7. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E69D2EA7A395]
 
Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: Results of an international expert panel meeting by the italian association of thoracic oncology (AIOT).
Gridelli C., Peters S., Mok T., Garassino M., Paz-Ares L., Attili I., de Marinis F., 2024/01. Lung cancer, 187 p. 107441. Peer-reviewed.
[DOI][Pmid][serval:BIB_9749AF3A1EE0]
iPSC-derived and Patient-Derived Organoids: Applications and challenges in scalability and reproducibility as pre-clinical models
Heinzelmann Elisa, Piraino Francesco, Costa Mariana, Roch Aline, Norkin Maxim, Garnier Virginie, Homicsko Krisztian, Brandenberg Nathalie, 2024. Current Research in Toxicology, 7 p. 100197.
[URN][DOI][WoS][serval:BIB_0D64D95B6A86]
 
Neo-adjuvant therapies for ER positive/HER2 negative breast cancers: from chemotherapy to hormonal therapy, CDK inhibitors, and beyond.
Stravodimou A., Voutsadakis I.A., 2024. Expert review of anticancer therapy, 24 (3-4) pp. 117-135. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8D56E74D4A72]
 
Reirradiation of head and neck squamous cell carcinomas: a pragmatic approach-part I: prognostic factors and indications to treatment.
Alterio D., Zaffaroni M., Bossi P., Dionisi F., Elicin O., Falzone A., Ferrari A., Jereczek-Fossa B.A., Sanguineti G., Szturz P. et al., 2024/01. La Radiologia medica, 129 (1) pp. 160-173. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1B37A4813CBC]
SAKK57/16 Nab-paclitaxel and Gemcitabine in Soft Tissue Sarcoma (NAPAGE): a phase I/II trial.
Digklia A., Kollár A., Dietrich D., Kronig M.N., Britschgi C., Rordorf T., Joerger M., Krasniqi F., Metaxas Y., Colombo I. et al., 2024/01. European journal of cancer, 197 p. 113470. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F4C4A8A8D1EB]
 
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.
Borghaei H., de Marinis F., Dumoulin D., Reynolds C., Theelen WSME, Percent I., Gutierrez Calderon V., Johnson M.L., Madroszyk-Flandin A., Garon E.B. et al., 2024/01. Annals of oncology, 35 (1) pp. 66-76. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1ED7B5418D24]
Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer.
Guarneri V., Passos Coelho J.L., Duhoux F.P., Egle D., García-Sáenz J.Á., Penault-Llorca F., Selander K., Wildiers H., Zaman K., Laeis P. et al., 2024. Future oncology, 20 (18) pp. 1237-1250. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7A3D7ED540BF]
 
The KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced malignancies.
Shapira-Frommer R., Niu J., Perets R., Peters S., Shouse G., Lugowska I., Garassino M.C., Sands J., Keenan T., Zhao B. et al., 2024. Future oncology, 20 (27) pp. 1983-1991. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0B8C6BE1D41B]
2023
Deep and lasting response and acquired resistance to BRAFV600E targeting in a low-grade ovarian cancer patient.
Anchisi S., Wolfer A., Bisig B., Missiglia E., Tiab A., Kamel E.M., Michielin O., Coukos G., Homicsko K., 2023/12/31. Cancer biology & therapy, 24 (1) p. 2193116. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_365141E36CC9]
5-Fluorouracil-associated severe hypertriglyceridaemia with positive rechallenge.
Giacomuzzi Moore B., Durigova A., Lamine F., Chtioui H., Salati E., 2023/12/19. BMJ case reports, 16 (12). Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_E970BBCD043C]
 
2023 MASCC/ESMO consensus antiemetic guidelines related to integrative and non-pharmacological therapies.
Molassiotis A., Affronti M.L., Fleury M., Olver I., Giusti R., Scotte F., 2023/12/16. Supportive care in cancer, 32 (1) p. 30. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_68A5B066F8D9]
 
Diagnostic et prise en charge de la tumeur à cellules géantes ténosynoviale [Diagnosis and management of tenosynovial giant cell tumor]
Bakota-Morrison C., Strasser R., Letovanec I., Digklia A., Stamatiou A., Omoumi P., Cherix S., 2023/12/13. Revue medicale suisse, 19 (854) pp. 2330-2335. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_E70F81166152]
 
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study.
Zeng Q., Klein C., Caruso S., Maille P., Allende D.S., Mínguez B., Iavarone M., Ningarhari M., Casadei-Gardini A., Pedica F. et al., 2023/12. The Lancet. Oncology, 24 (12) pp. 1411-1422. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5B5A44DC3272]
Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT).
Burns L., Hsu C.Y., Whisenant J.G., Marmarelis M.E., Presley C.J., Reckamp K.L., Khan H., Jo Fidler M., Bestvina C.M., Brahmer J. et al., 2023/12. Lung cancer, 186 p. 107423. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_399574E2CC5C]
Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON).
Garon E.B., Cho B.C., Luft A., Alatorre-Alexander J., Geater S.L., Kim S.W., Ursol G., Hussein M., Lim F.L., Yang C.T. et al., 2023/12. Lung cancer, 186 p. 107422. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_709D1EB4530B]
 
Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17.
Cathomas R., Rothschild S.I., Hayoz S., Bubendorf L., Özdemir B.C., Kiss B., Erdmann A., Aeppli S., Mach N., Strebel R.T. et al., 2023/11/20. Journal of clinical oncology, 41 (33) pp. 5131-5139. Peer-reviewed.
[DOI][Pmid][serval:BIB_A7A5826347FE]
 
Dépistage du cancer pulmonaire : vers l’implémentation d’un projet pilote en Suisse [Lung cancer screening : towards the implementation of a pilot project in Switzerland]
Bongard C., Rey Cobo J., Messe R., Noirez L., Lovis A., Krueger T., Peters S., Pozzessere C., Selby K., von Garnier C., 2023/11/15. Revue medicale suisse, 19 (850) pp. 2165-2171. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_C20779B2000E]
Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial.
Lim S.M., Peters S., Ortega Granados A.L., Pinto GDJ, Fuentes C.S., Lo Russo G., Schenker M., Ahn J.S., Reck M., Szijgyarto Z. et al., 2023/11/11. Nature communications, 14 (1) p. 7301. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D6E420A37DBF]
 
Corrigendum to "Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3369 patients in the ARCAD database" Eur J Cancer. 2023 Jan;178:162-170.
Margalit O., Harmsen W.S., Shacham-Shmueli E., Voss M.M., Boursi B., Wagner A.D., Cohen R., Olswold C.L., Saltz L.B., Goldstein D.A. et al., 2023/11. European journal of cancer, 194 p. 113339. Peer-reviewed.
[DOI][Pmid][serval:BIB_F88116DF20BF]
Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC.
Kim H.R., Awad M.M., Navarro A., Gottfried M., Peters S., Csőszi T., Cheema P.K., Rodriguez-Abreu D., Wollner M., Yang J.C. et al., 2023/11. JTO clinical and research reports, 4 (11) p. 100572. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_7EBE3AF70615]
Response of Brain and Meningeal Metastases to Trastuzumab-Deruxtecan in a Patient with HER2-Low Breast Cancer: A Case Report.
Wolf B., Dunet V., Dubruc E., Dolcan A., Nicod Lalonde M., Schiappacasse L., Zaman K., 2023/11. Case reports in oncology, 16 (1) pp. 1425-1435. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_7C9285AA6C6A]
The local microenvironment drives activation of neutrophils in human brain tumors.
Maas R.R., Soukup K., Fournier N., Massara M., Galland S., Kornete M., Wischnewski V., Lourenco J., Croci D., Álvarez-Prado Á.F. et al., 2023/10/12. Cell, 186 (21) pp. 4546-4566.e27. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_698367BEBBF8]
 
1452P Factors associated with real-world (rw) outcomes among pts with metastatic NSCLC (mNSCLC) receiving select immuno-oncology (IO) regimens: CORRELATE
Liu S.V., Salomonsen R.J-B., Diaz Perez I., Wang A., Cai L., Schmidt J., Sadow S., Peters S., 2023/10., ESMO Congress 2023, 20 - 24 October 2023 pp. S825-S826 dans Annals of Oncology.
[DOI][WoS][serval:BIB_549CA609CC08]
 
A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer.
Bobisse S., Bianchi V., Tanyi J.L., Sarivalasis A., Missiaglia E., Pétremand R., Benedetti F., Torigian D.A., Genolet R., Barras D. et al., 2023/10. Nature cancer, 4 (10) pp. 1410-1417. Peer-reviewed.
[DOI][Pmid][serval:BIB_E6692BB52E6C]
Cellular Therapy in NSCLC: Between Myth and Reality.
Imbimbo M., Wetterwald L., Friedlaender A., Parikh K., Addeo A., 2023/10. Current oncology reports, 25 (10) pp. 1161-1174. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2233B843CCB3]
Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13).
Novak U., Fehr M., Schär S., Dreyling M., Schmidt C., Derenzini E., Zander T., Hess G., Mey U., Ferrero S. et al., 2023/10. EClinicalMedicine, 64 p. 102221. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B8178ECC6BDA]
 
ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe.
Bayle A., Bonastre J., Chaltiel D., Latino N., Rouleau E., Peters S., Galotti M., Bricalli G., Besse B., Giuliani R., 2023/10. Annals of oncology, 34 (10) pp. 934-945. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_BB80FB84CE17]
 
Gender differences in tumor characteristics, treatment and survival of colorectal cancer: A population-based study.
van Erning F.N., Greidanus NEM, Verhoeven RHA, Buijsen J., de Wilt H.W., Wagner D., Creemers G.J., 2023/10. Cancer epidemiology, 86 p. 102441. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_639F911C9D12]
 
Immune-checkpoint inhibition for resectable non-small-cell lung cancer - opportunities and challenges.
Mountzios G., Remon J., Hendriks LEL, García-Campelo R., Rolfo C., Van Schil P., Forde P.M., Besse B., Subbiah V., Reck M. et al., 2023/10. Nature reviews. Clinical oncology, 20 (10) pp. 664-677. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0FB0D505E36B]
Leptomeningeal metastasis from solid tumours: EANO-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Le Rhun E., Weller M., van den Bent M., Brandsma D., Furtner J., Rudà R., Schadendorf D., Seoane J., Tonn J.C., Wesseling P. et al., 2023/10. ESMO open, 8 (5) p. 101624. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3F6C44F4DCB8]
Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study.
Kristeleit R., Leary A., Delord J.P., Moreno V., Oaknin A., Castellano D., Shappiro G.I., Fernández C., Kahatt C., Alfaro V. et al., 2023/10. Investigational new drugs, 41 (5) pp. 677-687. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_124EFD9C766F]
PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma.
Homicsko K., Zygoura P., Norkin M., Tissot S., Shakarishvili N., Popat S., Curioni-Fontecedro A., O'Brien M., Pope A., Shah R. et al., 2023/10. Journal for immunotherapy of cancer, 11 (10). Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_03AE420D2700]
Response to letter entitled: letter comments on: Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation.
Gosney J.R., Peters S., 2023/10. ESMO open, 8 (5) p. 101828. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_E0A055E006B6]
 
Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19
Gulati Shuchi, Hsu Chih-Yuan, Shah Surbhi, Shah Pankil K., Zon Rebecca, Alsamarai Susan, Awosika Joy, El-Bakouny Ziad, Bashir Babar, Beeghly Alicia et al., 2023/10/01. JAMA Oncology, 9 (10) p. 1390.
[DOI][WoS][Pmid][serval:BIB_12CBCEF74E70]
 
Very Long-Term Complete Remission Can Be Achieved in Men With High-Risk Localized Prostate Cancer and a Very High PSA Value: An Analysis of the GETUG 12 Phase 3 Trial.
Orlando V., Drubay D., Lavaud P., Faivre L., Lesaunier F., Delva R., Gravis G., Rolland F., Priou F., Ferrero J.M. et al., 2023/10. Clinical genitourinary cancer, 21 (5) pp. 615.e1-615.e8. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2588BC824A41]
Elevated liver function tests in a patient with breast cancer.
Neftel C., Zaman K., Chtioui H., Moradpour D., Sempoux C., Fraga M., 2023/09. Journal of hepatology, 79 (3) pp. e109-e111. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E70D878557D9]
Esophageal cancer T-staging on MRI: A preliminary study using cine and static MR sequences.
Haefliger L., Jreige M., Du Pasquier C., Ledoux J.B., Wagner D., Mantziari S., Shäfer M., Vietti Violi N., Dromain C., 2023/09. European journal of radiology, 166 p. 111001. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B3DB02D052A3]
 
European Epidemiology of Pleural Mesothelioma-Real-Life Data From a Joint Analysis of the Mesoscape Database of the European Thoracic Oncology Platform and the European Society of Thoracic Surgery Mesothelioma Database.
Opitz I., Bille A., Dafni U., Nackaerts K., Ampollini L., de Perrot M., Brcic L., Nadal E., Syrigos K., Gray S.G. et al., 2023/09. Journal of thoracic oncology, 18 (9) pp. 1233-1247. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_82EE065BEEA5]
Managing cisplatin-ineligible patients with resected, high-risk, locally advanced squamous cell carcinoma of the head and neck: Is there a standard of care?
Haddad R.I., Harrington K., Tahara M., Szturz P., Le Tourneau C., Salmio S., Bajars M., Lee N.Y., 2023/09. Cancer treatment reviews, 119 p. 102585. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_5948D827C4E9]
 
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.
Mellinghoff I.K., van den Bent M.J., Blumenthal D.T., Touat M., Peters K.B., Clarke J., Mendez J., Yust-Katz S., Welsh L., Mason W.P. et al., 2023/08/17. The New England journal of medicine, 389 (7) pp. 589-601. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0F3E3EF3CEF5]
Interdisciplinary Swiss consensus recommendations on staging and treatment of advanced prostate cancer.
Templeton A.J., Omlin A., Berthold D., Beyer J., Burger I.A., Eberli D., Engeler D., Fankhauser C., Fischer S., Gillessen S. et al., 2023/08/15. Swiss medical weekly, 153 p. 40108. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6C5E890FD075]
99mTc-macroaggregated albumin SPECT/CT predictive dosimetry and dose-response relationship in uveal melanoma liver metastases treated with first-line selective internal radiation therapy.
Tabotta F., Gnesin S., Dunet V., Ponti A., Digklia A., Boughdad S., Schaefer N., Prior J.O., Villard N., Tsoumakidou G. et al., 2023/08/12. Scientific reports, 13 (1) p. 13118. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_21F17BF36DB0]
 
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study.
Lee S.M., Schulz C., Prabhash K., Kowalski D., Szczesna A., Han B., Rittmeyer A., Talbot T., Vicente D., Califano R. et al., 2023/08/05. Lancet, 402 (10400) pp. 451-463. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4B87FA7A77E6]
 
Adjuvant Treatments for Surgically Resected Non-Small Cell Lung Cancer Harboring EGFR Mutations: A Review.
Passaro A., Mok TSK, Attili I., Wu Y.L., Tsuboi M., de Marinis F., Peters S., 2023/08/01. JAMA oncology, 9 (8) pp. 1124-1131. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_30B1F260B901]
Learning lessons from the COVID-19 pandemic for real-world evidence research in oncology-shared perspectives from international consortia.
Castelo-Branco L., Lee R., Brandão M., Cortellini A., Freitas A., Garassino M., Geukens T., Grivas P., Halabi S., Oliveira J. et al., 2023/08. ESMO open, 8 (4) p. 101596. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_5A744A2C49A9]
Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders' Collaborative Consortium (EORTC 1419).
Hertler C., Felsberg J., Gramatzki D., Le Rhun E., Clarke J., Soffietti R., Wick W., Chinot O., Ducray F., Roth P. et al., 2023/08. European journal of cancer, 189 p. 112913. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_58117B8EE829]
Modeling tumor size dynamics based on real-world electronic health records and image data in advanced melanoma patients receiving immunotherapy.
Courlet P., Abler D., Guidi M., Girard P., Amato F., Vietti Violi N., Dietz M., Guignard N., Wicky A., Latifyan S. et al., 2023/08. CPT, 12 (8) pp. 1170-1181. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A319336A78BD]
Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation.
Gosney J.R., Paz-Ares L., Jänne P., Kerr K.M., Leighl N.B., Lozano M.D., Malapelle U., Mok T., Sheffield B.S., Tufman A. et al., 2023/08. ESMO open, 8 (4) p. 101587. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0803E2B8A7EF]
 
Reirradiation of head and neck squamous cell carcinomas: a pragmatic approach, part II: radiation technique and fractionations.
Alterio D., Zaffaroni M., Bossi P., Dionisi F., Elicin O., Falzone A., Ferrari A., Jereczek-Fossa B.A., Sanguineti G., Szturz P. et al., 2023/08. La Radiologia medica, 128 (8) pp. 1007-1021. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_89918BD1D7ED]
 
STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines.
Proto C., Manglaviti S., Lo Russo G., Musca M., Galli G., Imbimbo M., Perrino M., Cordua N., Rulli E., Ballatore Z. et al., 2023/08. Journal of thoracic oncology, 18 (8) pp. 1070-1081. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7F9F91FE5CC5]
Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1.
Reck M., Ciuleanu T.E., Lee J.S., Schenker M., Zurawski B., Kim S.W., Mahave M., Alexandru A., Peters S., Pluzanski A. et al., 2023/08. Journal of thoracic oncology, 18 (8) pp. 1055-1069. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9890E6F11421]
Development of an eHealth-enhanced model of care for the monitoring and management of immune-related adverse events in patients treated with immune checkpoint inhibitors.
da Silva Lopes A.M., Colomer-Lahiguera S., Darnac C., Giacomini S., Bugeia S., Gutknecht G., Spurrier-Bernard G., Aedo-Lopez V., Mederos N., Latifyan S. et al., 2023/07/22. Supportive care in cancer, 31 (8) p. 484. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EC47A57CA4E0]
 
Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies.
Passaro A., Jänne P.A., Peters S., 2023/07/20. Journal of clinical oncology, 41 (21) pp. 3747-3761. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D5BA313EAC7F]
Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14.
König D., Savic Prince S., Hayoz S., Zens P., Berezowska S., Jochum W., Stauffer E., Braunersreuther V., Trachsel B., Thierstein S. et al., 2023/07/11. ESMO open, 8 (4) p. 101595. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_91D42041CEAF]
Phase 4 Multinational Multicenter Retrospective and Prospective Real-World Study of Nivolumab in Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
Gogate A., Bennett B., Poonja Z., Stewart G., Medina Colmenero A., Szturz P., Carrington C., Castro C., Gemmen E., Lau A. et al., 2023/07/09. Cancers, 15 (14) p. 3552. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_95F216A17E04]
Sex differences in treatment allocation and survival of potentially curable gastroesophageal cancer: A population-based study.
Kalff M.C., Dijksterhuis WPM, Wagner A.D., Oertelt-Prigione S., Verhoeven RHA, Lemmens VEPP, van Laarhoven HWM, Gisbertz S.S., van Berge Henegouwen M.I., 2023/07. European journal of cancer, 187 pp. 114-123. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_5B8DD083A7EC]
The Utility of ctDNA in Lung Cancer Clinical Research and Practice: A Systematic Review and Meta-Analysis of Clinical Studies.
Sun X., Abrahamson P., Ballew N., Kalilani L., Phiri K., Bell K.F., Slowley A., Zajac M., Hofstatter E., Stojadinovic A. et al., 2023/07. Cancer investigation, 41 (6) pp. 571-592. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F4BE601CAEA2]
Attracting Cavities 2.0: Improving the Flexibility and Robustness for Small-Molecule Docking.
Röhrig U.F., Goullieux M., Bugnon M., Zoete V., 2023/06/26. Journal of chemical information and modeling, 63 (12) pp. 3925-3940. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_38F1AA57EFDC]
Effects of food-based interventions in the management of chemoradiotherapy-induced nausea and vomiting: a systematic review.
Molassiotis A., Zhao I.Y., Crichton M., Olver I., Fleury M., Giusti R., Scotte F., Affronti M.L., 2023/06/23. Supportive care in cancer, 31 (7) p. 413. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F265AB431AEB]
 
Clinical and Demographic Characteristics, Mechanisms, and Outcomes in Patients With Acute Ischemic Stroke and Newly Diagnosed or Known Active Cancer.
Costamagna G., Hottinger A., Milionis H., Lambrou D., Salerno A., Strambo D., Livio F., Navi B.B., Michel P., 2023/06/13. Neurology, 100 (24) pp. e2477-e2489. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0F3BF5CF7627]
 
Outcomes of Stage IIIa and Well-Selected Stage IIIb or Oligometastatic Stage IV Non-Small Cell Lung Cancers Managed by Multimodal Therapy Including Immunotherapy and Surgery
Forster C, Abdelnour-Berchtold E, Chriqui L E, Bouchaab H, Peters S, Gonzalez M, Krueger T, Perentes J Y, 2023/06/09. dans British Journal of Surgery.
[DOI][WoS][serval:BIB_B98147D74089]
Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumors.
Schmidt J., Chiffelle J., Perez MAS, Magnin M., Bobisse S., Arnaud M., Genolet R., Cesbron J., Barras D., Navarro Rodrigo B. et al., 2023/06/06. Nature communications, 14 (1) p. 3188. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2898FB2D9415]
COVID-19 in cancer patients: update from the joint analysis of the ESMO-CoCARE, BSMO, and PSMO international databases.
Martin P., Tsourti Z., Ribeiro J., Castelo-Branco L., de Azambuja E., Gennatas S., Rogado J., Sekacheva M., Šušnjar S., Viñal D. et al., 2023/06. ESMO open, 8 (3) p. 101566. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_94155F804FBD]
Cytokine storm complicated by cardiogenic shock induced by anti-HER2 therapies.
Godinho R., Noto A., Fenwick C., Stravodimou A., Hugelshofer S., Peters S., Hullin R., Obeid M., 2023/06. Journal for immunotherapy of cancer, 11 (6). Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D3B4F544BDF7]
Defining the role of real-world data in cancer clinical research: The position of the European Organisation for Research and Treatment of Cancer.
Saesen R., Van Hemelrijck M., Bogaerts J., Booth C.M., Cornelissen J.J., Dekker A., Eisenhauer E.A., Freitas A., Gronchi A., Hernán M.A. et al., 2023/06. European journal of cancer, 186 pp. 52-61. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A0B1CC3E26F8]
Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial.
Girard N., Ponce Aix S., Cedres S., Berghmans T., Burgers S., Toffart A.C., Popat S., Janssens A., Gervais R., Hochstenbag M. et al., 2023/06. ESMO open, 8 (3) p. 101576. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B5CFBB1D0A86]
 
Feasibility of treatment with another CDK4/6 inhibitor after severe ribociclib liver toxicity.
Zurcher Jean-Philippe, Goujon Morgan, Cottu Paul H., Desmoulins Isabelle, Teixeira Luis, Mansi Laura, Meynard Guillaume, Dobi Erion, Rowinski Elise, Stacoffe Marion et al., 2023/06/01. pp. e13067-e13067 dans Journal of Clinical Oncology. Peer-reviewed.
[DOI][serval:BIB_B01DDDA0C38A]
 
Neoadjuvant immunotherapy for melanoma is now ready for clinical practice.
Garbe C., Dummer R., Amaral T., Amaria R.N., Ascierto P.A., Burton E.M., Dreno B., Eggermont AMM, Hauschild A., Hoeller C. et al., 2023/06. Nature medicine, 29 (6) pp. 1310-1312. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_079BED918172]
Optimal Delivery of Follow-Up Care Following Treatment for Adults Treated for Ewing Sarcoma.
Digklia A., Dolcan A., Kucharczyk M.A., Jones R.L., Napolitano A., 2023/06. Cancer management and research, 15 pp. 537-545. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A99279E44987]
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer.
Im S.A., Gennari A., Park Y.H., Kim J.H., Jiang Z.F., Gupta S., Fadjari T.H., Tamura K., Mastura M.Y., Abesamis-Tiambeng MLT et al., 2023/06. ESMO open, 8 (3) p. 101541. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_833FEAFDA3E9]
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer.
Yoshino T., Cervantes A., Bando H., Martinelli E., Oki E., Xu R.H., Mulansari N.A., Govind Babu K., Lee M.A., Tan C.K. et al., 2023/06. ESMO open, 8 (3) p. 101558. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_FC6A285A7C21]
Phenotypic diversity of T cells in human primary and metastatic brain tumors revealed by multiomic interrogation.
Wischnewski V., Maas R.R., Aruffo P.G., Soukup K., Galletti G., Kornete M., Galland S., Fournier N., Lilja J., Wirapati P. et al., 2023/06. Nature cancer, 4 (6) pp. 908-924. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AF8A124C7797]
Proposal of early CT morphological criteria for response of liver metastases to systemic treatments in gastroenteropancreatic neuroendocrine tumors: Alternatives to RECIST.
de Mestier L., Resche-Rigon M., Dromain C., Lamarca A., La Salvia A., de Baker L., Fehrenbach U., Pusceddu S., Colao A., Borbath I. et al., 2023/06. Journal of neuroendocrinology, 35 (6) pp. e13311. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_1A27AF92DDE2]
 
Simultaneous kinetics of oral vorinostat in plasma and cerebrospinal fluid in a patient with cutaneous T-cell lymphoma with CNS involvement.
Papadopoulou V., Degrauwe N., Decosterd L.A., Buclin T., Cairoli A., 2023/06. International journal of clinical pharmacology and therapeutics, 61 (6) pp. 270-272. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CC53A672C07F]
 
Spatial profiling of the microenvironment reveals low intratumoral heterogeneity and STK11-associated immune evasion in therapy-naïve lung adenocarcinomas.
Goldschmid H., Kluck K., Ball M., Kirchner M., Allgäuer M., Winter H., Herth F., Heußel C.P., Pullamsetti S.S., Savai R. et al., 2023/06. Lung cancer, 180 p. 107212. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_94DA50B976B3]
Tobacco cessation and the role of ESMO and medical oncologists: addressing the specific needs of cancer patients in times of the COVID-19 pandemic.
Krech R., Peters S., Kroemer H., Fu D., Giuliani R., Sehouli J., Ilbawi A., Prasad V., Ullrich A., 2023/06. ESMO open, 8 (3) p. 101579. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_348B9946FD46]
 
Cancer de la prostate à l’ère de la médecine de précision : un nouvel horizon [Prostate cancer in the era of precision medicine: a new horizon]
Nguyen-Ngoc T., Berthold D., Normand C., 2023/05/17. Revue medicale suisse, 19 (827) pp. 950-956. Peer-reviewed.
[DOI][Pmid][serval:BIB_1F5EA2E82D9D]
Cancer de l’endomètre : entre modernité et immunothérapie [Endometrial cancer in the crossroads of modernity and immunotherapy]
Giacomuzzi Moore B., Liapi A., Dolcan A., Kakourou A., Masmoudi S., Latifyan S., Sarivalasis A., 2023/05/17. Revue medicale suisse, 19 (827) pp. 944-949. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_0D5FCD171133]
Cancers des glandes salivaires : nouvelles approches thérapeutiques [Salivary gland cancer: new therapeutic approaches]
Herrera Gomez R.G., Mederos N., Szturz P., Degrauwe N., Jankovic J., Cristina V., 2023/05/17. Revue medicale suisse, 19 (827) pp. 958-963. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_44E8BFC57D5D]
Carrières en oncologie et leadership féminin : les progrès sont-ils au point mort ?
Peters S., Addeo A., Aapro M., 2023/05/17. Revue medicale suisse, 19 (827) pp. 929-930. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_DF4B416E037D]
Influence of corticosteroid treatment on CXCR4 expression in DLBCL.
Martin S., Viertl D., Janz A., Habringer S., Keller U., Schottelius M., 2023/05/10. EJNMMI research, 13 (1) p. 40. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_18B6F1DF4772]
Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi consensus study in Europe.
Kroese T.E., van Laarhoven HWM, Schoppman S.F., Deseyne PRAJ, van Cutsem E., Haustermans K., Nafteux P., Thomas M., Obermannova R., Mortensen H.R. et al., 2023/05. European journal of cancer, 185 pp. 28-39. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0D7216745F58]
Immunotherapy-based combinations in metastatic NSCLC.
Desai A., Peters S., 2023/05. Cancer treatment reviews, 116 p. 102545. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_74C72B664E9F]
 
Population pharmacokinetic modelling of tremelimumab in patients with advanced solid tumours and the impact of disease status on time-varying clearance.
Hwang M., Chia Y.L., Zheng Y., Chen C.C., He J., Song X., Zhou D., Goldberg S.B., Siu L.L., Planchard D. et al., 2023/05. British journal of clinical pharmacology, 89 (5) pp. 1601-1616. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_49EDEBE6BC65]
Semiautomated Pipeline to Quantify Tumor Evolution From Real-World Positron Emission Tomography/Computed Tomography Imaging.
Abler D., Courlet P., Dietz M., Gatta R., Girard P., Munafo A., Wicky A., Jreige M., Guidi M., Latifyan S. et al., 2023/05. JCO clinical cancer informatics, 7 pp. e2200126. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_D61806C1E839]
Adjuvant therapies in stages I-III epidermal growth factor receptor-mutated lung cancer: current and future perspectives.
Kris M.G., Mitsudomi T., Peters S., 2023/04/28. Translational lung cancer research, 12 (4) pp. 824-836. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_68C5CE6F566B]
Assessing the impact of digital patient monitoring on health outcomes and healthcare resource usage in addition to the feasibility of its combination with at-home treatment, in participants receiving systemic anticancer treatment in clinical practice: protocol for an interventional, open-label, multicountry platform study (ORIGAMA).
Iivanainen S., Baird A.M., Balas B., Bustillos A., Castro Sanchez A.Y., Eicher M., Golding S., Mueller-Ohldach M., Reig M., Welslau M. et al., 2023/04/19. BMJ open, 13 (4) pp. e063242. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_977B9654EEC3]
Baseline 18F-FDG PET/CT Radiomics in Classical Hodgkin’s Lymphoma: The Predictive Role of the Largest and the Hottest Lesions.
Triumbari EKA, Gatta R., Maiolo E., De Summa M., Boldrini L., Mayerhoefer M.E., Hohaus S., Nardo L., Morland D., Annunziata S., 2023/04/11. Diagnostics, 13 (8) p. 1391. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_C94C68D79B02]
 
A global collaboRAtive study of CIC-rearranged, BCOR::CCNB3-rearranged and other ultra-rare unclassified undifferentiated small round cell sarcomas (GRACefUl).
Palmerini E., Gambarotti M., Italiano A., Nathenson M.J., Ratan R., Dileo P., Provenzano S., Jones R.L., DuBois S.G., Martin-Broto J. et al., 2023/04. European journal of cancer, 183 pp. 11-23. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_514E63DE5157]
Challenges in oncology career: are we closing the gender gap? Results of the new ESMO Women for Oncology Committee survey.
Linardou H., Adjei A.A., Bajpai J., Banerjee S., Berghoff A.S., Mathias C.C., Choo S.P., Dent R., Felip E., Furness AJS et al., 2023/04. ESMO open, 8 (2) p. 100781. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F95E2DE28E52]
 
Immunotherapy in the first-line treatment of elderly patients with advanced non-small-cell lung cancer: results of an International Experts Panel Meeting by the Italian Association of Thoracic Oncology (AIOT).
Gridelli C., Peters S., Velcheti V., Attili I., de Marinis F., 2023/04. ESMO open, 8 (2) p. 101192. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6ABA6C8DB138]
 
Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Hendriks L.E., Kerr K.M., Menis J., Mok T.S., Nestle U., Passaro A., Peters S., Planchard D., Smit E.F., Solomon B.J. et al., 2023/04. Annals of oncology, 34 (4) pp. 358-376. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0E714965871B]
 
Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Hendriks L.E., Kerr K.M., Menis J., Mok T.S., Nestle U., Passaro A., Peters S., Planchard D., Smit E.F., Solomon B.J. et al., 2023/04. Annals of oncology, 34 (4) pp. 339-357. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2DAD09CAD00B]
Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study.
Joerger M., Hundsberger T., Haefliger S., von Moos R., Hottinger A.F., Kaindl T., Engelhardt M., Marszewska M., Lane H., Roth P. et al., 2023/04. Investigational new drugs, 41 (2) pp. 267-275. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8938B103AA5D]
 
The SERENITY study: online Mindfulness-Based Cancer Recovery (e-MBCR) program for women living with breast and gynecological cancer—protocol for a pilot effectiveness-implementation randomized trial
Gaignard Marie-Estelle, Stanic Jelena, Bodmer Alexandre, Zaman Khalil, Sarivalasis Apostolos, Labidi-Galy Intidhar, Jermann Francoise, Di Marco Mariagrazia, Ljuslin Michael, Ryser Stephan et al., 2023/04. Journal of Psychosocial Oncology Research &amp; Practice, 5 (2).
[DOI][serval:BIB_837DAB9F23E5]
Toxicity, quality of life, and PSA control after 50 Gy stereotactic body radiation therapy to the dominant intraprostatic nodule with the use of a rectal spacer: results of a phase I/II study.
Cloitre M., Valerio M., Mampuya A., Rakauskas A., Berthold D., Tawadros T., Meuwly J.Y., Heym L., Duclos F., Vallet V. et al., 2023/04/01. The British journal of radiology, 96 (1145) p. 20220803. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CB3AC2C2AFDE]
 
A neutrophil response linked to tumor control in immunotherapy.
Gungabeesoon J., Gort-Freitas N.A., Kiss M., Bolli E., Messemaker M., Siwicki M., Hicham M., Bill R., Koch P., Cianciaruso C. et al., 2023/03/30. Cell, 186 (7) pp. 1448-1464.e20. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_75BDBCD58180]
Le régime cétogène : efficace contre le cancer ? [Is ketogenic diet effective against cancer ?]
Tankeu A.T., Barigou M., Pedro R., De Micheli R., Bodmer A., Genton L., Collet T.H., Tran C., 2023/03/22. Revue medicale suisse, 19 (819) pp. 576-580. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_E4266B1D898E]
QuantImage v2: a comprehensive and integrated physician-centered cloud platform for radiomics and machine learning research.
Abler D., Schaer R., Oreiller V., Verma H., Reichenbach J., Aidonopoulos O., Evéquoz F., Jreige M., Prior J.O., Depeursinge A., 2023/03/22. European radiology experimental, 7 (1) p. 16. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EBB87EC8BBD4]
A multicenter phase II trial of anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative breast cancer.
Mamot C., Wicki A., Hasler-Strub U., Riniker S., Li Q., Holer L., Bärtschi D., Zaman K., von Moos R., Dedes K.J. et al., 2023/03/06. Scientific reports, 13 (1) p. 3705. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8ADF8CFC0053]
 
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial.
de Langen A.J., Johnson M.L., Mazieres J., Dingemans A.C., Mountzios G., Pless M., Wolf J., Schuler M., Lena H., Skoulidis F. et al., 2023/03/04. Lancet, 401 (10378) pp. 733-746. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_610E00846F6E]
 
The Landscape and Therapeutic Targeting of BRCA1, BRCA2 and Other DNA Damage Response Genes in Pancreatic Cancer.
Voutsadakis I.A., Digklia A., 2023/03/03. Current issues in molecular biology, 45 (3) pp. 2105-2120. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5BA72940A3F2]
 
Assoziation von KRAS/STK11/KEAP1 Mutationen und Outcome in der POSEIDON Studie: Durvalumab+/− Tremelimumab+Chemotherapie beim metastasierten NSCLC (mNSCLC)
Reinmuth N, Peters S, Cho B, Luft A, Alatorre-Alexander J, Geater S, Kim S, Ursol G, Hussein M, Lim F et al., 2023/03. dans 63. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V..
[DOI][WoS][serval:BIB_BEC283C28682]
 
Clear cell sarcoma: state-of-the art and perspectives.
Wetterwald L., Riggi N., Kyriazoglou A., Dei Tos G., Dei Tos A., Digklia A., 2023/03. Expert review of anticancer therapy, 23 (3) pp. 235-242. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E565DF943C91]
Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides BRCA1 and BRCA2 as Breast Cancer Biomarkers for PARP Inhibitors and Other DDR Targeting Therapies.
Voutsadakis I.A., Stravodimou A., 2023/03. Anticancer research, 43 (3) pp. 967-981. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3961434FC488]
Phase I Study of Androgen Deprivation Therapy in Combination with Anti-PD-1 in Melanoma Patients Pretreated with Anti-PD-1.
Robert C., Lebbé C., Lesimple T., Lundström E., Nicolas V., Gavillet B., Crompton P., Baroudjian B., Routier E., Lejeune F.J., 2023/03/01. Clinical cancer research, 29 (5) pp. 858-865. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_04775354DA15]
 
Single Seminal Vesicle Metastasis From Dorsal Melanoma Detected by 18 F-FDG PET/CT and Confirmed by Biopsy.
Testart Dardel N., Isenborghs E., Valerio M., Michielin O., Schaefer N., 2023/03/01. Clinical nuclear medicine, 48 (3) pp. e151-e152. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E552B0535E6B]
Response and Resistance to Trametinib in MAP2K1-Mutant Triple-Negative Melanoma.
Krebs F.S., Moura B., Missiaglia E., Aedo-Lopez V., Michielin O., Tsantoulis P., Bisig B., Trimech M., Zoete V., Homicsko K., 2023/02/24. International journal of molecular sciences, 24 (5) p. 4520. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E3A48A3138B7]
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study.
Johnson M.L., Cho B.C., Luft A., Alatorre-Alexander J., Geater S.L., Laktionov K., Kim S.W., Ursol G., Hussein M., Lim F.L. et al., 2023/02/20. Journal of clinical oncology, 41 (6) pp. 1213-1227. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_50248B9218E8]
Dendritic cells direct circadian anti-tumour immune responses.
Wang C., Barnoud C., Cenerenti M., Sun M., Caffa I., Kizil B., Bill R., Liu Y., Pick R., Garnier L. et al., 2023/02. Nature, 614 (7946) pp. 136-143. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_33489F389D05]
Drug-drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure.
Raoul J.L., Moreau-Bachelard C., Gilabert M., Edeline J., Frénel J.S., 2023/02. ESMO open, 8 (1) p. 100880. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_8D75F775A9EA]
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer.
Koppikar S., Oaknin A., Babu K.G., Lorusso D., Gupta S., Wu L.Y., Rajabto W., Harano K., Hong S.H., Malik R.A. et al., 2023/02. ESMO open, 8 (1) p. 100774. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_236602D3C3F5]
Pancreatic adenocarcinomas without KRAS, TP53, CDKN2A and SMAD4 mutations and CDKN2A/CDKN2B copy number alterations: a review of the genomic landscape to unveil therapeutic avenues.
Voutsadakis I.A., Digklia A., 2023/02. Chinese clinical oncology, 12 (1) p. 2. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_173A16DC9A8B]
 
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in Older Patients: Are New Agents Bringing New Hope?
Cossu Rocca M., Lorini L., Szturz P., Bossi P., Vermorken J.B., 2023/02. Drugs & aging, 40 (2) pp. 135-143. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4C168665F905]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University